INVA Projected Dividend Yield
Innoviva Inc ( NASDAQ : INVA )Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Co. is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. Co.'s products include GIAPREZA and XERAVA. 21 YEAR PERFORMANCE RESULTS |
INVA Dividend History Detail INVA Dividend News INVA Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |